Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Julie Wolfson-Stockman M.D.
Associate Professor
Close
E-mail
wolfsonj@uab.edu
Links
Provider Directory
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Julie Wolfson-Stockman M.D.
Associate Professor
Positions
Member (C)
,
Institute for Cancer Outcomes & Survivorship
,
School of Medicine
Associate Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
Associate Scientist
,
Cancer Control and Population Sciences
,
O'Neal Comprehensive Cancer Center
Associate Scientist (C)
,
Center for Women's Reproductive Health
,
General Clinical Research Center
Associate Professor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
Publications
Research
Background
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2022
Altered mental status as a presentation of rhabdomyolysis in a patient with sickle cell anemia
.
Pediatric Blood and Cancer
. 69.
2022
2022
COVID-19 in Children with Cancer
.
Current Oncology Reports
. 24:295-302.
2022
2022
How can we create resilient research systems in a pandemic?
.
Cancer
. 128:651-653.
2022
2022
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
.
Blood Advances
. 6:679-685.
2022
2022
Expenditures in Young Adults with Hodgkin Lymphoma: NCI-Designated Comprehensive Cancer Centers versus Other Sites
.
Cancer Epidemiology, Biomarkers and Prevention
. 31:142-149.
2022
2021
SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities
.
Journal of Clinical Oncology
. 39:3778-3788.
2021
2021
Adherence to cardiomyopathy screening guidelines among adolescent and young adult cancer survivors exposed to chest radiation and/or anthracyclines
.
Journal of Cancer Survivorship
. 15:738-747.
2021
2021
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
.
Pediatric Blood and Cancer
. 68.
2021
2021
Risk, Racial Disparity, and Outcomes among Patients with Cancer and COVID-19 Infection
.
JAMA Oncology
. 7:1064-1065.
2021
2021
Expenditures among young adults with acute lymphoblastic leukemia by site of care
.
Cancer
. 127:1901-1911.
2021
2021
Poverty and Survival in Childhood Cancer: A Framework to Move Toward Systemic Change
2021
2020
Preventive health service use among survivors of adolescent and young adult cancer
.
Preventive Medicine Reports
. 20.
2020
2020
Isolation of DNA-free RNA from human bone marrow mononuclear cells: Comparison of laboratory methods
2020
2019
Lung cancer in nonelderly patients: Facility and patient characteristics associated with not receiving treatment
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 17:931-939.
2019
2018
Causes of inferior outcome in adolescents and young adults with acute lymphoblastic leukemia: Across oncology services and regardless of clinical trial enrollment
.
Cancer Epidemiology, Biomarkers and Prevention
. 27:1133-1141.
2018
2017
T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib)
.
Blood Advances
. 1:2724-2728.
2017
2017
Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma
.
Leukemia
. 31:1450-1453.
2017
2017
Publication outcomes of abstracts from the American Society of Hematology Annual Meeting
.
American Journal of Hematology
. 92:E81-E83.
2017
2017
Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia: Impact of care at specialized cancer centers on survival outcome
.
Cancer Epidemiology, Biomarkers and Prevention
. 26:312-320.
2017
2016
Value, access, and cost of cancer care delivery at academic cancer centers
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 14:837-847.
2016
2015
Impact of tailored education on awareness of personal risk for therapy-related complications among childhood cancer survivors
.
Journal of Clinical Oncology
. 33:3887-3893.
2015
2015
Impact of care at comprehensive cancer centers on outcome: Results from a population-based study
.
Cancer
. 121:3885-3893.
2015
2015
Long-term pulmonary function in survivors of childhood cancer
.
Journal of Clinical Oncology
. 33:1592-1600.
2015
2015
Piecing together the puzzle of disparities in adolescents and young adults
.
Cancer
. 121:1168-1171.
2015
2014
Impact of care at NCI Comprehensive Cancer Centers (NCICCC) on cancer outcome: Results from a population-based study.
.
Journal of Clinical Oncology
. 32:188.
2014
2014
Impact of treatment site in adolescents and young adults with central nervous system tumors
2014
2013
Pitfalls of using administrative data sets to describe clinical outcomes in sickle cell disease
.
Pediatric Blood and Cancer
. 60:1936-1939.
2013
2013
Relapse after treatment of pediatric hodgkin lymphoma: Outcome and role of surveillance after end of therapy
.
Pediatric Blood and Cancer
. 60:1458-1463.
2013
2013
Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.
.
British Journal of Haematology
. 162:376-382.
2013
2012
Sickle cell disease in California: Sociodemographic predictors of emergency department utilization
.
Pediatric Blood and Cancer
. 58:66-73.
2012
2011
Sickle-cell disease in California: A population-based description of emergency department utilization
.
Pediatric Blood and Cancer
. 56:413-419.
2011
2010
Health care reform 2010: Expected favorable impact on childhood cancer patients and survivors
.
Cancer Journal
. 16:554-562.
2010
Chapter
Filter
Year
Title
Altmetric
2017
Making Ends Meet: Financial Issues from the Perspectives of Patients and Their Health-Care Team
. 667-685.
2017
Research
Principal Investigator On
A Comprehensive Investigation of Outcome Disparities in Children, Adolescents and Young Adults with Cancer
awarded by
KAUL PEDIATRIC RESEARCH INSTITUTE
Adolescents and Young Adults with Cancer: Race, Ethnicity & Treatment Site
awarded by
St. Baldrick's Foundation
CHOP NCORP - COG Study Chair
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CHOP NCORP - COG Study Chair
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CHOP NCORP - COG Study Chair
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Cancer Care Delivery Study Chair
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Continuation of Tyrosine Kinase Inhibitors after Chemotherapy in Pediatric Ph+ ALL: A Multi-site Retrospective Study
awarded by
Stanford University
Follow-Up Care and Preventive Service Use Among Survivors of Adolescent and Young Adult Cancer
awarded by
Kaiser Permanente
PediCARE
awarded by
DANA-FARBER CANCER INSTITUTE INC
Pediatric Oncology COVID Cancer Case Report - A National Registry of Children with Cancer (POCC)
awarded by
Concern Foundation
Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
awarded by
National Cancer Institute/NIH/DHHS
Understanding Causes of Outcome Disparities in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
awarded by
HYUNDAI HOPE ON WHEELS
Understanding Outcome Disparities in AYA with ALL
awarded by
RALLY FOUNDATION
Understanding Outcome Disparities in AYA with ALL
awarded by
RALLY FOUNDATION
Understanding Outcome Disparities in AYA with ALL
awarded by
RALLY FOUNDATION
Investigator On
A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects from 1 To < 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
A Phase I/II Study of Bosutinib in Pediatric Patients with Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia, Study ITCC-054/COG AAML1921
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467,NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AAML 1031 - Bayer
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AAML1831A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations”
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
ADVANCING ALSTATE (Alabama Lifespan Sickle cell Tracking Access Towards Equality) Network
awarded by
CDC - Centers for Disease Control and Prevention/DHHS
ADVL1712: A Phase I Trial of Pevonedistat Given in Combination with Fludarabine, Cytarabine, and Azacitidine in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ALTE1631, A Randomized Web-Based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
APEC1621I -NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Alliance for Clinical Trials in Oncology Payment Agreement
awarded by
MAYO CLINIC
Alliance for Clinical Trials in Oncology Payment Agreement
awarded by
MAYO CLINIC
An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CTSU: Phase II Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Cookies for Kids' Cancer Phase 1 Supplemental
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Developing a Network to Utilize Administrative and Clinical Data for Childhood, Adolescent and Young Adult Oncology Survivorship Research
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Hyundai Hope on Wheels Impact Grant
awarded by
HYUNDAI HOPE ON WHEELS
Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors
awarded by
University of Wisconsin-Milwaukee
PEPCTN1812 - A Phase 1 Trial of the CD123 X CD3 Dual Affinity Re-Targeting Antibody Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
PER CASE REIMBURSEMENT NCORP Operations Grant 7UG1CA189955 -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Private Grant
awarded by
NOVARTIS PHARMACEUTICALS CORPORATION
Private Grant
awarded by
JANSSEN RESEARCH & DEVELOPMENT, LLC
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
Project EveryChild APEC14B1
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Project Everychild APEC14B1
awarded by
CHILDREN'S ONCOLOGY GROUP
Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma
awarded by
NEW YORK MEDICAL COLLEGE
St. Baldrick's Foundation Supplemental Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
St. Baldricks Fdn Supplemental Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Workload Intensity NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Background
Education And Training
MassGeneral Hospital for Children, Internship
Masachusetts General Hospital, Residency
Children's Hospital Los Angeles, Postdoctoral Fellowship
Doctor of Medicine,
University of Florida
2002
Contact
Full Name
Julie
Wolfson-Stockman